Overview
Corporate Strategy Analyst – Associate/Senior Associate Level Jobs in Greater Los Angeles, CA at Immix Biopharma (Nasdaq: IMMX)
Title: Corporate Strategy Analyst – Associate/Senior Associate Level
Company: Immix Biopharma (Nasdaq: IMMX)
Location: Greater Los Angeles, CA
Corporate Strategy Analyst – Associate/Senior Associate Level
Los Angeles, CA / Hybrid
Our Values
· Integrity
· Intelligence
· Initiative
What You Will Do
- Create and complete internal financial models and presentations
- Pipeline – Participate in determining development strategy for pipeline therapeutic candidates
- Participate in developing corporate strategy for possible new therapeutic pipeline
- Create and complete proforma models to evaluate opportunities
What We Look For
Prior investment banking / equity research / private equity / management consulting experience
Prior experience analyzing biopharmaceutical strategies
Prior Scientific Research Publications, Good Laboratory Practices, Experience in Early Drug Development a plus
Education: At least Bachelors degree.
MD, PhD and/or MS a plus
About Immix
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
